Cyclo Therapeutics Inc - Class A
CYTH
|
$1.26
8.62%
7.94%
84K
|
Professional, Scientific, and T...
(0.0% 1d) (-11.9% 1m) (57.5% 1y) (0.0% 2d) (0.0% 3d) (5.0% 7d) (46.45% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 36,181,832
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
cholesterol genetic alzheimer alzheimer’s
add to watch list Paper trade email alert is off
Press-releases
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-18 (Crawled : 15:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -6.06%
H: 10.32%
C: 3.23%
RFL 4 | $1.74 -1.14% 0.0% 7K
|
Finance
|
| O: -1.16%
H: 3.51%
C: -0.58%
business year update therapeutics financial results
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Published: 2024-03-13 (Crawled : 21:00) - globenewswire.com
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -3.09%
H: 8.92%
C: -1.27%
RFL 4 | $1.74 -1.14% 0.0% 7K
|
Finance
|
| O: -1.2%
H: 6.06%
C: 4.24%
financial results
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: 6.43%
H: 1.58%
C: -2.75%
patent disease alzheimer’s treatment application therapeutics
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: 8.03%
H: 0.54%
C: -6.76%
trappsol fda disease positive treatment meeting program therapeutics
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -0.74%
H: 0.0%
C: -8.15%
therapeutics
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Published: 2023-11-15 (Crawled : 15:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -10.88%
H: 13.74%
C: 10.69%
RFL 4 | $1.74 -1.14% 0.0% 7K
|
Finance
|
| O: 3.87%
H: 0.0%
C: -4.79%
AMTI 4 | $0.263 -14.3% -1.14% 0
|
Health Technology
|
| O: -10.29%
H: 16.6%
C: 9.53%
therapeutics financial results
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
Published: 2023-10-23 (Crawled : 13:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: 6.27%
H: 2.0%
C: 1.0%
RFL 4 | $1.74 -1.14% 0.0% 7K
|
Finance
|
| O: -2.37%
H: 3.64%
C: -10.91%
management therapeutics
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -3.33%
H: 1.72%
C: -0.86%
conference therapeutics
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
Published: 2023-09-21 (Crawled : 13:30) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -3.13%
H: 3.83%
C: -1.94%
AMTI 4 | $0.263 -14.3% -1.14% 0
|
Health Technology
|
| O: 32.26%
H: 0.0%
C: 0.0%
agreement molecular
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Published: 2023-08-15 (Crawled : 14:00) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -4.1%
H: 1.41%
C: -4.29%
RFL 4 | $1.74 -1.14% 0.0% 7K
|
Finance
|
| O: 0.0%
H: 0.0%
C: -3.9%
therapeutics financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Last 48 Hours Insiders Buying
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.43 1.03% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.56 0.28% 0.28% 11K
|
Consumer Non-Durables
|
20:10